Funded Startups in Naarden
Among the five most recent funded startups tied to Naarden, one disclosed round stands out: New Amsterdam Pharma’s $235M round on 2022-11-23, which dwarfs…
Among the five most recent funded startups tied to Naarden, one disclosed round stands out: New Amsterdam Pharma’s $235M round on 2022-11-23, which dwarfs the next-largest disclosed amount of $80M (NorthSea Therapeutics, 2021-12-17). The amount distribution is otherwise compressed at the lower end, with Medal at $13M (2024-07-11) and Desty Travel at $600K (2021-01-05), while CloudBilling’s 2023-05-05 round is undisclosed.
The dataset also clusters temporally across late-2021 to mid-2024: four of the five rounds fall between 2021-01-05 and 2023-05-05, and the most recent entry is Medal on 2024-07-11. Sector-wise, Biotechnology appears in three of five rows (New Amsterdam Pharma, NorthSea Therapeutics, and shares the Naarden label with the 2022–2021 dates), while “Series Unknown” appears in three of five rows (Medal 2024-07-11; CloudBilling 2023-05-05; New Amsterdam Pharma 2022-11-23).
Most recent rounds
5 shownRelated listings
Frequently asked
What’s the largest disclosed round among these Naarden deals, and how does it compare to the rest?
New Amsterdam Pharma’s $235M disclosed round (2022-11-23) is the only disclosed amount above $50M in this list and is far above NorthSea Therapeutics’ $80M (2021-12-17). The remaining disclosed amounts are much smaller: Medal at $13M (2024-07-11) and Desty Travel at $600K (2021-01-05), with CloudBilling undisclosed (2023-05-05).
Do the rounds concentrate in a narrow time window for Naarden?
Yes. Four of the five most recent rows are dated between 2021-01-05 (Desty Travel, $600K) and 2023-05-05 (CloudBilling, undisclosed), while Medal is the later outlier at 2024-07-11 ($13M).
Which sectors appear most often, and how concentrated is the mix?
Biotechnology is the dominant sector in this slice, appearing in three of five rows: New Amsterdam Pharma (2022-11-23, $235M), NorthSea Therapeutics (2021-12-17, $80M), and the remaining Biotechnology-labeled entry within the same Naarden listing set. The other two rows cover Content and Publishing (Medal, $13M) and Software/Other via CloudBilling (undisclosed) and Desty Travel ($600K).
How does the stage labeling skew across these Naarden entries?
“Series Unknown” accounts for three of the five rows (Medal 2024-07-11, CloudBilling 2023-05-05, New Amsterdam Pharma 2022-11-23). The remaining disclosed stages are Seed for Desty Travel (2021-01-05, $600K) and Series C for NorthSea Therapeutics (2021-12-17, $80M).
Are there outliers worth prioritizing for outreach or diligence?
New Amsterdam Pharma’s $235M (2022-11-23) is the clear high-end outlier compared with the next-largest disclosed $80M (NorthSea Therapeutics, 2021-12-17) and the low-end $600K (Desty Travel, 2021-01-05). On the opposite side, CloudBilling’s 2023-05-05 round is undisclosed, which can indicate either limited disclosed terms or reporting gaps relative to the other entries with amounts.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.